Phathom Pharmaceuticals, Inc.
PHAT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $1 | $1 | $0 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $1 | $1 | $0 |
| Enterprise Value | $1 | $1 | $1 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 25.3% | 38.5% | -3.9% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 87.5% | 87.2% | 86.9% | 87.1% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -27.7% | -147.1% | -266.7% | -187.7% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -60.5% | -191.9% | -330.7% | -251% |
| EPS Diluted | -0.41 | -1.05 | -1.31 | -1.05 |
| % Growth | 61% | 19.8% | -24.8% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |